Investment analysts at BTIG Research initiated coverage on shares of Misonix (NASDAQ:MSON) in a research note issued to investors on Wednesday, Briefing.com Automated Import reports. The firm set a “buy” rating and a $29.00 price target on the medical equipment provider’s stock. BTIG Research’s price target suggests a potential upside of 21.04% from the company’s current price.
Shares of NASDAQ MSON opened at $23.96 on Wednesday. Misonix has a 12 month low of $12.20 and a 12 month high of $26.41.
Misonix (NASDAQ:MSON) last issued its quarterly earnings results on Wednesday, May 8th. The medical equipment provider reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. The business had revenue of $9.56 million during the quarter. Misonix had a negative net margin of 18.10% and a negative return on equity of 29.13%.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its holdings in Misonix by 10.8% in the third quarter. Renaissance Technologies LLC now owns 231,899 shares of the medical equipment provider’s stock valued at $4,290,000 after purchasing an additional 22,599 shares during the period. Vanguard Group Inc. grew its holdings in Misonix by 15.7% in the third quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock valued at $3,941,000 after purchasing an additional 28,889 shares during the period. Vanguard Group Inc grew its holdings in Misonix by 15.7% in the third quarter. Vanguard Group Inc now owns 213,040 shares of the medical equipment provider’s stock valued at $3,941,000 after purchasing an additional 28,889 shares during the period. Essex Investment Management Co. LLC purchased a new stake in Misonix in the first quarter valued at approximately $1,688,000. Finally, Bridgeway Capital Management Inc. grew its holdings in Misonix by 24.3% in the third quarter. Bridgeway Capital Management Inc. now owns 68,100 shares of the medical equipment provider’s stock valued at $1,260,000 after purchasing an additional 13,300 shares during the period. Institutional investors and hedge funds own 21.17% of the company’s stock.
Misonix Company Profile
Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.
Read More: What is a growth and income fund?
Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.